Previsión

No hay datos de analistas disponibles para esta empresa.

Noticias Ir al feed de noticias

Oncopeptides: revenue in second quarter rises 62%, shares jump

Oncopeptides reported net sales of SEK 31.1m in Q2 2026, up 62% year‑on‑year, and SEK 56.5m in the first half (+74%). Gross margin in H1 was 98%, the EBIT loss narrowed to SEK 86.2m, and operating costs fell slightly. The company reported SEK 158m in cash after a March rights issue and reiterated its target to reach positive cash flow in 2027. The share rose about 10% in early trading but remains well below the 52‑week high. » Más en de.investing.com
Oncopeptides: Q3 revenue rises 174% – profitability targeted by end of 2026

Oncopeptides reports Q3 2025 revenue of SEK 20.2m, up 174% year‑on‑year, and a gross margin of 99%. EBIT improved to -SEK 47.1m but remained negative, while operating expenses were slightly reduced. After an oversubscribed rights issue, liquidity stands at SEK 147.9m; the company aims for positive cash flow by the end of 2026. Oncopeptides is advancing commercialization in Europe (Germany, Spain, Italy) and is negotiating partnerships in Japan, but uncertainty over growth and timing failed to reassure investors, sending the stock down nearly 14%. » Más en de.investing.com
Oncopeptides achieves 174% revenue increase, stock falls sharply in pre-market

Oncopeptides reported Q3 2025 net revenue growth of 174% to SEK 20.2m and a gross profit of SEK 19.9m with a gross margin of 99%. Operating expenses fell 3% and EBIT improved from -SEK 61.3m to -SEK 47.1m; after a capital raise liquidity stands at SEK 147.9m. Despite the progress, the stock fell 12.44% in pre-market trading as investors voiced concerns about operational challenges, market expansion and the timeline to profitability by end-2026. Management plans to expand its market presence in Europe and will present further details at the capital markets day on 13 November. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Oncopeptides tuvo unos ingresos de 2,32 Mio€ y un beneficio neto de −2,94 Mio€

(EUR)	mar 2026	YoY
Ingresos	+2,32 Mio	89,95%
Beneficio bruto	+2,29 Mio	86,38%
Beneficio neto	−2,94 Mio	47,33%
EBITDA	−3,72 Mio	32,47%

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+36,05 Mio€
Número de acciones	241,96 Mio
Máximo/mínimo de 52 semanas	+0,59€ - +0,11€
Dividendos	No
Beta	-1,33
Ratio P/E	−1,76
Ratio PEG	−0,04
Ratio P/B	+5,77
Ratio P/S	+4,80

Perfil de la empresa

Oncopeptides AB (publ), ein Biotech-Unternehmen, entwickelt in den Vereinigten Staaten, Europa und international Arzneimittel zur Behandlung von Krebs. Der führende Produktkandidat ist Melflufen, ein Peptid-Wirkstoff-Konjugat zur Behandlung des rezidivierenden, refraktären multiplen Myeloms bei erwachsenen Patienten. Oncopeptides AB (publ) wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Stockholm, Schweden.